

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 000	<p>INITIAL COMMENTS</p> <p>An annual survey was completed on December 4, 2025. A deficiency was cited.</p> <p>This facility is licensed for the following service category: 10A NCAC 27G .5600C Supervised Living for Adults with Developmental Disability.</p> <p>This facility is licensed for 6 and has a current census of 5. The survey sample consisted of audits of 3 current clients.</p>	V 000		
V 118	<p>27G .0209 (C) Medication Requirements</p> <p>10A NCAC 27G .0209 MEDICATION REQUIREMENTS</p> <p>(c) Medication administration:</p> <p>(1) Prescription or non-prescription drugs shall only be administered to a client on the written order of a person authorized by law to prescribe drugs.</p> <p>(2) Medications shall be self-administered by clients only when authorized in writing by the client's physician.</p> <p>(3) Medications, including injections, shall be administered only by licensed persons, or by unlicensed persons trained by a registered nurse, pharmacist or other legally qualified person and privileged to prepare and administer medications.</p> <p>(4) A Medication Administration Record (MAR) of all drugs administered to each client must be kept current. Medications administered shall be recorded immediately after administration. The MAR is to include the following:</p> <p>(A) client's name;</p> <p>(B) name, strength, and quantity of the drug;</p> <p>(C) instructions for administering the drug;</p> <p>(D) date and time the drug is administered; and</p> <p>(E) name or initials of person administering the drug.</p>	V 118		

Division of Health Service Regulation
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE _____ TITLE _____ (X6) DATE _____

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 118	<p>Continued From page 1</p> <p>(5) Client requests for medication changes or checks shall be recorded and kept with the MAR file followed up by appointment or consultation with a physician.</p> <p>This Rule is not met as evidenced by: Based on observation, record reviews and interviews, the facility failed to keep the MAR current affecting one of three audited clients (#3). The findings are:</p> <p>Reviews on 12/3/25 and 12/4/25 of client #3's record revealed: -Date of admission was 6/12/23. -Diagnoses was Autistic Disorder; Major Depressive Disorder, Single Episode, Unspecified; Generalized Anxiety Disorder.</p> <p>Review on 12/3/25 of a physician's order for client #3 revealed: -Order dated 11/3/25 for Amlodipine Besylate-Benazepril HCL 10-20 milligrams (mg) (Hypertension/Chest Pain), one capsule by mouth daily.</p> <p>Review on 12/4/25 of physician's orders for client #3 revealed: -Order dated 8/7/25 for Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily. -Order dated 5/6/25 for Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily. -Order dated 2/6/25 for Amlodipine</p>	V 118		

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 118	<p>Continued From page 2</p> <p>Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily.</p> <p>Observation of client #3's medication on 12/3/25 at approximately 1:09 pm revealed: -Amlodipine Besylate-Benazepril HCL 10-20 mg was available. - Amlodipine Besylate-Benazepril HCL 10-20 mg was dispensed on 10/24/25.</p> <p>Review on 12/4/25 of the licensee's electronic record for client #3 revealed: -A discontinue (D/C) order dated 8/7/25 for Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily. -This entry was labeled "Awaiting acknowledgement." -It was "still processing."</p> <p>Reviews on 12/3/25 and 12/4/25 of MARs for client #3 revealed: -Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily, was not documented as administered on the MARs 5/1/25-12/3/25. -Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily, was grayed out on the MARs 4/25/25-4/30/25. -Amlodipine Besylate-Benazepril HCL 10-20 mg, one capsule by mouth daily, was documented as administered on the MARs 2/1/25-4/24/25. -The MAR for April, 2025 identified the Supervisor/House Manager 1 as the individual who changed the MAR on 4/24/25.</p> <p>Interview on 11/3/25 with client #3 revealed: -He knew which medication he took daily. -He got the Amlodipine Besylate-Benazepril HCL daily. It was never missed.</p> <p>Interview on 11/4/25 with the Pharmacist</p>	V 118		

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 118	<p>Continued From page 3</p> <p>revealed:</p> <ul style="list-style-type: none"> -They have only dispensed the Amlodipine Besylate-Benazepril HCL 10-20 mg dose for client #3. -They have never sent a D/C order. -She doesn't know why there would be a D/C order in the licensee's electronic record. -The last prescription was filled and sent to the facility 11/21/25. <p>Interview on 12/4/25 with staff #1 revealed:</p> <ul style="list-style-type: none"> -She administered the Amlodipine Besylate-Benazepril HCL 10-20 mg to client #3 daily. -She thought the Amlodipine Besylate-Benazepril HCL 10-20 mg was listed on the MARs since April, 2025. -"I don't have an answer" for why she was administering the Amlodipine Besylate-Benazepril HCL 10-20 mg and not documenting it. -She thought she was documenting it. -If she had noticed it was not on the MARs she would have asked management about it. -She and her coworker "have to stay on (Supervisor/House Manager 1)" about keeping medications current on the MARs. -She doesn't understand how the Amlodipine Besylate-Benazepril HCL 10-20 mg could have gone so long being administered but not being on the MARs. <p>Interview on 12/3/25 with staff #2 revealed:</p> <ul style="list-style-type: none"> -She was not aware of any medication errors. -She administered the Amlodipine Besylate-Benazepril HCL 10-20 mg to client #3 daily. -She didn't know why the Amlodipine Besylate-Benazepril HCL 10-20 mg was not written on the MARs. 	V 118		

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 118	<p>Continued From page 4</p> <p>Interview on 12/4/25 with staff #2 revealed: -She knew that the Amlodipine Besylate-Benazepril HCL 10-20 mg was not on the MARs. -Normally when a medication was D/C'd Supervisor/House Manager 1 would inform the staff that it had been D/C'd. They were not told this by Supervisor/House Manager 1 so staff #2 continued to administer the Amlodipine Besylate-Benazepril HCL 10-20 mg despite it not being listed on the MARs. -She never told anyone that the Amlodipine Besylate-Benazepril HCL 10-20 mg was not listed on the MARs.</p> <p>Interviews on 12/3/25 and 12/4/25 with the Qualified Professional revealed: -Supervisor/House Manager 1 is currently on vacation and a substitute (Supervisor/House Manager 2) is covering his work while he is gone. -She was not aware of any medication errors. -She is not responsible for keeping the MARs current regarding adding medication changes or taking medications off of the MARs when they are D/C'd. -Supervisor/House Manager 1 was responsible for keeping the MARs current. -She did not administer medication. -She didn't know for sure why the Amlodipine Besylate-Benazepril HCL 10-20 mg was not on the MARs for client #3. -After discussing it with Supervisor/House Manager 2 she thought this may have been due to a miscommunication with the pharmacy or a misunderstanding of the pharmacy's communication with Supervisor/House Manager 1. -She confirmed the MARs were not kept current for client #3.</p>	V 118		

Division of Health Service Regulation

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: MHL004-003	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____ B. WING _____	(X3) DATE SURVEY COMPLETED 12/04/2025
--	---	---	---

NAME OF PROVIDER OR SUPPLIER ANSON GROUP HOME	STREET ADDRESS, CITY, STATE, ZIP CODE 405 BURNS STREET WADESBORO, NC 28170
---	--

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
V 118	<p>Continued From page 5</p> <p>Interview on 12/3/25 with Supervisor/House Manager 1 revealed:</p> <ul style="list-style-type: none"> -He was responsible for keeping the MARs current including making any changes to the medication listed on the MARs and taking medication off the MARs when it is D/C'd. -When medication was added or changed the doctor sent that information to the pharmacy. The pharmacy then notified Supervisor/House Manager 1 through the licensee's electronic records system of the changes to be made to the MARs. -If he was not notified through the electronic system he wouldn't know to make the change on the MARs. -He didn't know why the Amlodipine Besylate-Benazepril HCL 10-20 mg was not listed on the MARs. 	V 118		